In This Article:
Tesla (TSLA)
Fresh sales data on Tuesday showed continued poor performance for electric vehicle maker Tesla (TSLA) in Europe, amid backlash against CEO Elon Musk's political activities.
Official data showed that Tesla (TSLA) registered 3,157 car sales in France in March, which was down nearly 37% from last year, according to a Reuters report. Meanwhile, Tesla (TSLA) was said to have registered 911 sales in Sweden last month, which represented a fall of 64% from same period last year.
Read more: FTSE 100 LIVE: Stocks head higher despite tariff anxieties
This comes after data released last week showed that Tesla's (TSLA) market share in Europe continued to fall year-on-year in February. Data from the European Automobile Manufacturers Association (ACEA) showed that Tesla (TSLA) had sold 42.6% fewer vehicles in Europe in January and February.
Musk, a close adviser to US president Donald Trump, has made a number of high profile interventions in European politics. There have been protests at Tesla (TSLA) dealerships across the world, particularly in the US, demonstrating against Musk's role in politics, in heading up the so-called US Department of Government Efficiency (DOGE) and overseeing cuts to government agencies.
Tesla (TSLA) shares fell 1.7% on Monday but were up 3.8% in pre-market trading on Tuesday.
Moderna (MRNA)
Shares in Moderna (MRNA) sunk nearly 9% on Monday, after it was announced over the weekend that US Food and Drug Administration (FDA) top vaccine official Peter Marks has resigned.
In his resignation letter, Marks raised concerns about the anti-vaccine beliefs of Health and Human Services (HHS) secretary Robert F Kennedy Jr and whether the new FDA head, Marty Makary, would be able to stand up to them.
Read more: Gold climbs to new highs as investors brace for Trump tariffs
"Efforts currently being advanced by some on the adverse health effects of vaccination are concerning," Marks wrote. "Undermining confidence in well-established vaccines ... is irresponsible, detrimental to public health, and a clear danger to our nation’s health, safety, and security."
Other vaccine biotech stocks that fell on Monday on the back of the news included Novavax (NVAX), which fell more than 8%. BioNTech (BNTX) was down more than 4%, Dynavex (DVAX) declined 5%, and Vaxcyte (PCVX) plummeted nearly 46%.
Newsmax (NMAX)
Shares in conservative media outlet Newsmax skyrocketed 735% in their market debut on Monday, closing the session on $83.51 and giving the company a market valuation of $10.7bn.
Newsmax (NMAX) said in a report on Monday that it raised $75m (£58m) in its initial public offering (IPO) on Friday, as well as $225m in a private preferred offering, which closed in February.